A research study to look at the distribution and effects of coramitug on amyloid deposits in heart tissue using PET/CT imaging in people with ATTR amyloidosis
NN6019-7853
Phase 1 other active
Quick answer
A research study to look at the distribution and effects of coramitug on amyloid deposits in heart tissue using PET/CT imaging in people with ATTR amyloidosis for transthyretin amyloid amyloidosis cardiomyopathy (ATTR-CM) is a Phase 1 program (other) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- transthyretin amyloid amyloidosis cardiomyopathy (ATTR-CM)
- Phase
- Phase 1
- Modality
- other
- Status
- active